奥曲肽联合FOLFOX方案化疗治疗晚期大肠癌疗效观察  

Clinical observation of the curative effect of octreotide combined with FOLFOX regiment on advanced colorectal cancer

作　　者：徐冬云[1] 张南征[1] 徐永茂[1] 

机构地区：[1]中国人民解放军第97医院消化肿瘤科,江苏徐州221004

出　　处：《徐州医学院学报》2010年第7期474-476,共3页Acta Academiae Medicinae Xuzhou

摘　　要：目的观察奥曲肽(OCT)联合FOLFOX方案化疗治疗晚期大肠癌的临床疗效及安全性。方法 58例晚期大肠癌患者随机分为2组:治疗组30例,采用OCT联合FOLFOX方案化疗;对照组28例,采用FOLFOX方案化疗,至少用药2周期,以近期疗效、体力情况(KPS)评分、血清癌胚抗原(CEA)及不良反应为观察指标。结果治疗组近期有效率、KPS评分改善率、血清CEA阳性降低率显著高于对照组(P<0.05)。两组均无严重不良反应发生。结论 OCT联合FOLFOX方案化疗可提高晚期大肠癌疗效,不良反应可耐受。Objective To investigate the efficacy and safety of octreotide（OCT） combined with FOLFOX regimen in the treatment of advanced colorectal cancer.Methods 58 cases of advanced colorectal cancer were randomized into treatment group（n=30）,treated with OCT combined with FOLFOX regimen and the control group（n=28）,treated with FOLFOX regimen.After at least 2 courses,the recent efficacy,KPS scores,serum CEA and adverse reactions were analyzed.Results The recent efficacy rate was significantly higher in the treatment group（50.00%） than in the control group（39.30%）（P0.05）.The KPS score improvement of the treatment group（60.00%） was obviously superior to that of the control group（42.86%）（P0.05）.The serum CEA-positive reduction rate of the treatment group（46.96%） was significantly larger than that of the control group（30.63%）（P0.05）.There were no serious adverse reactions in either group.Conclusion OCT combined with FOLFOX regimen is effective and well-tolerated in patients with advanced colorectal cancer.

关 键 词：大肠癌 化学疗法 奥曲肽 

分 类 号：R735.34[医药卫生—肿瘤]